UPDATE: Canaccord Lowers PT on Hologic from $24 to $23

Canaccord maintained a Buy rating on Hologic HOLX and lowered its price target from $24 to $23. Canaccord wrote, “We maintain our BUY rating and adjust our PT to $23 from $24, ahead of the closing of the Gen-Probe acquisition. We favor the potential outputs of the acquisition– namely sales synergies and potential for cash flow accretion and growth augmentation. We also remain constructive regarding growth potential of the Breast Health business – namely potential inflection point with 3D Tomo over the next 18-24 months.” Hologic closed at $18.26 on Monday.